Terminated PHASE4 INTERVENTIONAL 2-arm NCT00434278

A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease

Sponsor: Genentech, Inc.

Conditions Cystic Fibrosis

Interventions Dornase alfa placebo

Updated 11 times since 2017 Last updated: May 12, 2017 Started: Mar 31, 2007 Primary completion: Nov 30, 2008 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study was terminated for administrative reasons. There were no safety concerns.

Other terminated trials from Genentech, Inc.

More terminations from Genentech, Inc.

Other Cystic Fibrosis trials with similar outcome

Browse all Cystic Fibrosis trials

A PHASE4 clinical study on Cystic Fibrosis, this trial is terminated or withdrawn. The trial is conducted by Genentech, Inc. and has accumulated 11 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE4
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE4
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE4

▶ Show 6 earlier versions

Dec 2021 — Dec 2022 [monthly]

Terminated PHASE4
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4
Jul 2017 — Jun 2018 [monthly]

Terminated PHASE4
Feb 2017 — Jul 2017 [monthly]

Terminated PHASE4
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE4

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.

Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Albuquerque, United States , Ann Arbor, United States , Atlanta, United States , Augusta, United States , Birmingham, United States , Charleston, United States , Chicago, United States , Cleveland, United States , Columbia, United States and 29 more locations